Nice to see Pato's are fully underwriting the rights issue ... plus Mansour is partially sub-underwriting the issue.
Nice tick of approval for PeriCoach.
The value proposition is simple (as stated in today's release) - $600 on incontinence pads p.a. (a real and on-going expense) that only treats the symptoms vs half that for PeriCoach with the potential to provide a cure.
Seems a no brainer to me. Also always nice when the cap raising comes in near your buy in price!
Add to My Watchlist
What is My Watchlist?